Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 30:e57 2007
DOI: 10.2337/dc07-0220
© 2007 by the American Diabetes Association
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nicolucci, A.
Right arrow Articles by Tognoni, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nicolucci, A.
Right arrow Articles by Tognoni, G.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Online Letters: Comments and Responses

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

Response to Buse et al.

Antonio Nicolucci, MD, Giorgia De Berardis, MSC PHARM CHEM, Michele Sacco, MD and Gianni Tognoni, MD

From the Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro, Chieti, Italy

Address correspondence to Antonio Nicolucci, MD, Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale 8/A, 66030 S. Maria Imbaro (CH), Italy. E-mail: nicolucci{at}negrisud.it

The recent American Diabetes Association/American Heart Association statement recommends the use of low doses of aspirin as a strategy for primary prevention of cardiovascular diseases in all individuals with diabetes aged >40 years or who have additional risk factors (1). Like in previous recommendations (2), only selected pieces of evidence are mentioned to support this statement. The data used to sustain the efficacy of aspirin come from the Early Treatment Diabetic Retinopathy Study, the only study specifically conducted in diabetic patients with and without previous cardiovascular disease (3). In this trial, treatment with 650 mg aspirin for 5 years was associated with a nonsignificant 9% reduction in the primary end point (vascular death, nonfatal myocardial infarction, or nonfatal stroke). On the other hand, the results of the last meta-analysis on the efficacy of antiplatelet therapy in the prevention of major cardiovascular events are not discussed (4). The meta-analysis documented a clear benefit for the whole population (22% reduction in the risk of major cardiovascular events) but not for the subgroup of diabetic patients (7% risk reduction). Likewise, the Primary Prevention Project, involving over 1,000 diabetic patients, showed that low-dose aspirin only marginally reduced the risk of major cardiovascular events (RR 0.90 [95% CI 0.50–1.62]) (5). More recently, results of the Women's Health Study documented in 1,027 women with diabetes that treatment with low-dose aspirin was associated with a nonsignificant 10% reduction in the risk of major cardiovascular events as compared with placebo (0.90 [0.63–1.29]). The overall effect was the result of a reduction in the risk of stroke (0.46 [0.25–0.85]), associated with an increased risk of myocardial infarction (1.48 [0.88–2.49]) (6).

Overall, existing data suggest that the clinical efficacy of low-dose aspirin in patients with diabetes is substantially lower than in individuals without diabetes. Indeed, a growing body of evidence supports the hypothesis that diabetes might represent a special case of aspirin resistance (7). Therefore, existing recommendations seem mainly based on extrapolations from data on other high-risk groups, rather than a comprehensive review of pertinent data, under the assumption that diabetes is a cardiovascular disease risk equivalent.

The need for sound, reliable evidence is underlined by the activation of several large-scale randomized trials (ASCEND [A Study of Cardiovascular Events in Diabetes], POPADAD [Prevention of Progression of Asymptomatic Diabetic Arterial Disease], ACCEPT-D [Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes], and J-PAD [Japanese Primary Prevention of Atherosclerosis WithAspirin for Diabetes]) currently under way. In the meantime, the decision to prescribe aspirin should be taken on an individual patient basis, after a careful evaluation of the balance between the expected benefits and the risk of major bleeding (8). Will aspirin benefits outweigh the risks in patients younger than 50 years of age, without additional cardiovascular risk factors? Should aspirin be prescribed to patients over 70 years of age, considering the lack of reliable information in this age-group and the sharp increase in the risk of upper gastrointestinal bleeding? (9). If the lower-than-expected benefit of aspirin in diabetes will be confirmed by ongoing trials, its use for primary prevention of vascular disease in unselected people will result in net harm. To this respect, it is worth noting that the Food and Drug Administration did not support using aspirin for the primary prevention of heart attacks in moderate-risk patients.

References

  1. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 30:162–172, 2007[Abstract/Free Full Text]
  2. American Diabetes Association: Aspirin therapy in diabetes (Position Statement). Diabetes Care 27(Suppl. 1):S72–S73, 2004
  3. ETDRS Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14. JAMA 268:1292–1300, 1992[Abstract]
  4. Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86, 2002[Abstract/Free Full Text]
  5. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, on behalf of the PPP Collaborative Group: Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264–3272, 2003[Abstract/Free Full Text]
  6. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352:1293–1304, 2005[Abstract/Free Full Text]
  7. Evangelista V, Totani L, Rotondo S, Lorenzet R, Tognoni G, De Berardis G, Nicolucci A: Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost 93:8–16, 2005[Medline]
  8. McQuaid KR, Laine L: Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 119:624–638, 2006[Medline]
  9. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C: Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373–2383, 2005[Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
J. B. Buse, M. P. Pignone, and for the ADA/AHA Primary Prevention Consensus Panel
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association: Response to Nicolucci et al.
Diabetes Care, June 1, 2007; 30(6): e58 - e58.
[Full Text] [PDF]

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nicolucci, A.
Right arrow Articles by Tognoni, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nicolucci, A.
Right arrow Articles by Tognoni, G.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum